Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea (DD): A prospective assessment

被引：0
|
作者：
Misset, JL
Saliba, F
Giacchetti, S
Brain, E
Vassal, G
Bonnay, M
Bastian, G
Cote, C
Mahjoubi, M
Herait, P
Hagipantelli, R
Cvitkovic, E
机构：
[1] HOP PAUL BROUSSE,VILLEJUIF,FRANCE
[2] IGR,VILLEJUIF,FRANCE
[3] SOMPS,PARIS,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：742 / 742
页数：1
相关论文
共 50 条
  • [31] Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression
    Fang, Zhong-Ze
    Zhang, Dunfang
    Cao, Yun-Feng
    Xie, Cen
    Lu, Dan
    Sun, Dong-Xue
    Tanaka, Naoki
    Jiang, Changtao
    Chen, Qianming
    Chen, Yu
    Wang, Haina
    Gonzalez, Frank J.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2016, 291 : 21 - 27
  • [32] A pilot study of irinotecan hydrochloride (CPT-11) plus cisplatin (CDDP) as salvage therapy for relapsed and refractory ATLL
    Fukushima, Takuya
    Yoshida, Shinichiro
    Hata, Tomoko
    Miyazaki, Yasushi
    Tsukasaki, Kunihiro
    Ikeda, Shuichi
    Tomonaga, Masao
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (04) : 630 - 631
  • [33] Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11
    Ikeda, M
    Yasui, M
    Fukunaga, H
    Seshimo, I
    Takayama, O
    Ikenaga, M
    Yamamoto, H
    Ohue, M
    Sekimoto, M
    Monden, M
    EUROPEAN JOURNAL OF CANCER CARE, 2005, 14 (05) : 435 - 439
  • [34] Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer
    Karthaus, M
    Ballo, H
    Abenhardt, W
    Steinmetz, T
    Geer, T
    Schimke, J
    Braumann, D
    Behrens, R
    Behringer, D
    Kindler, M
    Messmann, H
    Boeck, HP
    Greinwald, R
    Kleeberg, U
    ONCOLOGY, 2005, 68 (4-6) : 326 - 332
  • [35] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Manabu Shiozawa
    Nobuhiro Sugano
    Kazuhito Tsuchida
    Soichiro Morinaga
    Makoto Akaike
    Yukio Sugimasa
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 365 - 370
  • [36] A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma
    Mühr-Wilkenshoff, F
    Hinkelbein, W
    Ohnesorge, I
    Wolf, KJ
    Riecken, EO
    Zeitz, M
    Scherübl, H
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2003, 18 (04) : 330 - 334
  • [37] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Shiozawa, Manabu
    Sugano, Nobuhiro
    Tsuchida, Kazuhito
    Morinaga, Soichiro
    Akaike, Makoto
    Sugimasa, Yukio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (03) : 365 - 370
  • [38] Response of hepatoblastoma heavily treated and relapsed in the transplanted liverto single-agent therapy with irinotecan hydrochloride (CPT-11).
    Ijichi, O
    Isikawa, S
    Shinkoda, Y
    Tanabe, T
    Takamatsu, H
    Inomata, Y
    Kawano, Y
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 68 - 68
  • [39] A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma
    F. Mühr-Wilkenshoff
    W. Hinkelbein
    I. Ohnesorge
    K. J. Wolf
    E.-O. Riecken
    M. Zeitz
    H. Scherübl
    International Journal of Colorectal Disease, 2003, 18 : 330 - 334
  • [40] Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model
    Meng, Jingjing
    Abu, Yaa F.
    Zhang, Yue
    Zhou, Yuyin
    Xie, Yun
    Yan, Yan
    Tao, Junyi
    Ramakrishnan, Sundaram
    Chen, Chi
    Roy, Sabita
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 (10) : 1362 - 1378
12345